Get Your Rear in Gear 5K races and other events are scheduled in many cities in 2011 to get people to talk about colorectal cancer — with their families, their friends, and their doctors.
During March 2011 there are Get Your Rear in Gear Runs in the following cities. Click on a city near you for more information about registration and times. Read the rest of this entry »
As the Australian government considers the future of its National Bowel Cancer Screening Program, Australian and US researchers provide compelling evidence of the cost-effectiveness of expanding the national screening program.
Australia has one of the highest colorectal cancer (CRC) mortality rates in the world. Its current screening program (costing about $29 million a year) provides a one-time immunochemical fecal test (iFOBT) for people aged 50, 55, and 65 years. Program funding expires in mid-2011.
A study funded by the Australian government and the US National Cancer Institute, published in the Feb. 21 Medical Journal of Australia, found that expanding the program to screen all 5 million Australians aged 50 -74 years every two years by iFOBT could end up costing only about $50 million more a year, while saving 300 to 500 lives every year.
March and Colorectal Cancer Awareness Month are almost here.
If you are running a race — or sponsoring a walk — to raise awareness and funds for colorectal cancer, let us know. We’ll post it here on Research News.
Be sure to give us a link so people can find you and send the details of where, when, and how to sign up.
Email kate@fightcolorectalcancer.org with information about your event.
Thanks to KidsPrintables.com for the runner image. It’s available there for your kids to color along with other fun things to do this winter.
Are you finished with surgery or chemotherapy for early stage colon cancer?
Would you like a chance to see if a new experimental treatment can reduce your risk of
Researchers at the National Surgical Adjuvant Breast and Bowel Project (NSABP) would like to talk to you about a clinical trial exploring whether a statin drug can reduce the risk of new polyps, colon cancer recurrence, or a new primary colon cancer.
In the P-5 clinical trial stage I and II colon cancer patients will be randomly assigned to take either rosuvastatin (Crestor®) or an inert placebo for five years. Read the rest of this entry »
The recall of Jantoven® warfarin 3 mg tablets issued on February 16th has been expanded to include more dosages and additional medicines.
Jantoven and other medications that were packaged on the same Upsher-Smith Laboratories packaging line between May and November of 2010 are all being recalled as a precaution after 10 mg Jantoven tablets were found in a bottle labeled 3 mg.
Since warfarin is used to prevent blood clots in many people with cancer, it is critical that you check your medicine to be sure that it isn’t part of the Upsher-Smith recall.
A complete description of the recalled pills is available on the FDA website including the tablet color and dose. All recalled Jantoven tablets are scored and imprinted with WFR and the number 832. Read the rest of this entry »
